

SIXTH MEETING OF THE VECTOR CONTROL ADVISORY GROUP

VCAAG



GENEVA, SWITZERLAND
26-28 APRIL 2017



**World Health
Organization**

The support provided by the Bill and Melinda Gates Foundation (Grant No OPP1032376) for the work of Vector Control Advisory Group is gratefully acknowledged.

This report was produced by the Vector Ecology and Management Unit, Department of Control of Neglected Tropical Diseases, and the Entomology and Vector Control of the Global Malaria Programme of the World Health Organization.

Design & Layout: Patrick Tissot WHO/HTM/NTD

SIXTH MEETING OF THE VECTOR CONTROL ADVISORY GROUP

VCAAG

GENEVA, SWITZERLAND
26–28 APRIL 2017



**World Health
Organization**



© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Sixth meeting of the Vector Control Advisory Group. Geneva, Switzerland, 26–28 April 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Please consult the WHO Neglected Tropical Diseases website for the most up-to-date version of all documents (www.who.int/neglected_diseases/en)

Printed in France.

WHO/HTM/NTD/VEM/2017.05

CONTENTS

1. SUMMARY -----	1
2. BACKGROUND -----	2
3. POLICY DEVELOPMENT FOR NEW PRODUCTS AND PRODUCT CLASSES FOR CONTROL OF VECTOR-BORNE DISEASES -----	3
4. RECOMMENDATIONS FROM THE EXPERT ADVISORY GROUP ON EPIDEMIOLOGICAL TRIAL DESIGNS -----	5
5. GUIDANCE FOR TESTING THE EFFICACY OF VECTOR CONTROL PRODUCTS -----	7
5.1 Manual on epidemiological study design -----	7
5.2 Guidelines on efficacy testing of vector traps -----	7
6. CONCLUSIONS AND RECOMMENDATIONS ON NEW VECTOR CONTROL PRODUCT CLASSES -----	9
6.1 Yorkool LN G2.0 and G2.1 – initial assessment and guidance on data generation -----	9
6.2 Interceptor G2 – update and guidance on data generation -----	9
6.3 <i>wMel Wolbachia</i> – update on randomized controlled trials and pilot deployment -----	11
6.4 OX513A <i>Aedes aegypti</i> – update on randomized controlled trials and pilot deployment -----	12
6.5 Spatial repellents – update on trial design and statistical methodology -----	12
7. DISCUSSION -----	15
ANNEXES -----	16
Annex 1. Agenda -----	16
Annex 2. List of participants -----	18
Annex 3. Declaration of interests -----	20

1. SUMMARY

The sixth meeting of the Vector Control Advisory Group (VCAG) was held at the headquarters of the World Health Organization (WHO) in Geneva, Switzerland on 26–28 April 2017. The objectives of the meeting were to review and provide guidance on potential new vector control tools for use in public health and to discuss the requirements for data and epidemiological study designs to demonstrate the epidemiological efficacy of new tools.

VCAG reviewed updates on progress in developing and assessing products in its portfolio (including Yorkool LN G2.0 and G2.1, Interceptor G2, Spatial Repellents, wMel *Wolbachia Aedes aegypti* and OX513A *Aedes aegypti*), two guidance documents (one on trial design, the other on vector traps) and the outcomes of a WHO Expert Advisory Group meeting on study design for vector control trials (Geneva, 24–25 April 2017).

DECLARATIONS OF INTEREST

All the invited experts completed a declaration of interests form, which was submitted to and reviewed by the Secretariat before the meeting. A summary of any declared interests is given in *Annex 3*.

2. BACKGROUND

VCAG was established in 2012 as an independent advisory body to WHO to review and provide advice on the public health value of new tools and approaches for the prevention and control of vector-borne diseases. The role of VCAG is to:

- conduct an initial review of a new intervention concept and determine which data are required to (i) validate the product class, claim or variation, (ii) determine the public health value, (iii) support the formulation of a WHO policy recommendation;
- advise WHO and applicants on the process for generating the required data;
- assess the data for new vector control tools and approaches once it has been generated to determine whether the public health value of a new product has been demonstrated;
- develop or refine the target product profiles of new vector control classes; and
- provide recommendations to guide policy development.

The purpose of the meeting was to review and provide guidance to innovators on the data requirements for a number of technologies including new long-lasting insecticidal nets (LLINs) claiming efficacy against mosquitoes that are resistant to insecticides as well as several other well-advanced technologies in the VCAG portfolio. The group was briefed on: (i) an advanced draft of an information note on the revised process for evaluating vector control products; (ii) the conclusions of an expert advisory group meeting convened under VCAG on appropriate trial designs for epidemiological data generation (Geneva, 24–25 April 2017); and reviewed (iii) an advanced draft manual on epidemiological study design; and (iv) other guidance documents under development, including a draft manual on efficacy testing of vector traps for control of Aedes-borne diseases and guidance on the field testing of genetically modified mosquitoes with driving transgenes for malaria control.

The meeting was held in open and closed sessions. The open sessions were attended by stakeholders and observers. The closed sessions were restricted to VCAG experts and members of the WHO Secretariat. The meeting agenda is given in *Annex 1* and the list of participants in *Annex 2*.

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>